# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 20 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT S564ce60f6d
CUTOFF DATE (today): 2024-05-30
Regulator: FDA (US)
Matter: FDA draft guidance: Voluntary Malfunction Summary Reporting Program for Manufacturers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sd65b57b1a2
CUTOFF DATE (today): 2022-01-18
Regulator: FDA (US)
Matter: FDA draft guidance: Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S3c50127b06
CUTOFF DATE (today): 2023-02-24
Regulator: FDA (US)
Matter: FDA draft guidance: Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2021-05-21 | official-forward (B) | draft_guidance_availability_notice | "Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products." The draft guidance, when finalized, will represent the current thinking of FDA on adju
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products." The draft guidance, when finalized, will represent the current thinking of FDA on adjusting for covariates in randomized clinical trials for drugs and biologics. This draft guidance revises the draft guidance "Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biologics with Continuous Outcomes" that published April 25, 2019. This revision provides more detailed recommendations for the use of linear models for covariate adjustment and also includes recommendations for covariate adjustment using nonlinear models.
---
## SNAPSHOT S4ebd608030
CUTOFF DATE (today): 2025-11-17
Regulator: SEBI (IN)
Matter: SEBI consultation: easing IPO lock-in mechanics for pledged shares and requiring an abridged prospectus at the draft-offer-document stage
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sb23d5d0736
CUTOFF DATE (today): 2026-05-18
Regulator: SEBI (IN)
Matter: SEBI consultation: revising the method for calculating variable net worth of stock brokers
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-04-24 | official-forward (B) | consultation_paper | "Consultation paper on Review of variable net worth for stock brokers" | www.sebi.gov.in
   Claims: Proposes a revised method for calculating the 'variable net worth' stock brokers must maintain, replacing the 2022 method based on average daily client cash balance. / States the 2022 method is no longer effective because the upstreaming framework now requires brokers to transfer client funds to clearing members/clearing corporations, leaving minimal client cash with brokers. / The proposed draft circular, developed by a Working Group of NSE, BSE and Broker Associations, sets out an alternative calculation method for public comment.
   Excerpt: As part of comprehensive risk management framework and to protect the interest of investors by aligning the net worth requirement with the operational risk being taken by the stock broker ('broker') with respect to its clients, the concept of variable net worth was introduced vide SEBI (Stock Brokers) (Amendment) Regulations, 2022... with the introduction of upstreaming framework mandating that clients' funds shall be up-streamed by broker to clearing members/clearing corporations, there is minimal amount of cash balance of clients which is retained by broker. Consequently, calculation of variable net worth of the brokers based on availability of funds with them may not be an effective way of calculating variable net worth.
---
## SNAPSHOT Scb1b9b5004
CUTOFF DATE (today): 2023-08-18
Regulator: FDA (US)
Matter: FDA draft guidance: Charging for Investigational Drugs Under an Investigational New Drug Application: Questions and Answers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Scb856082b3
CUTOFF DATE (today): 2021-07-29
Regulator: FDA (US)
Matter: FDA draft guidance: Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S9332025d1a
CUTOFF DATE (today): 2026-05-26
Regulator: SEBI (IN)
Matter: SEBI consultation: framework for an IT Resilience Index for market infrastructure institutions
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-03-25 | official-forward (B) | consultation_paper | "Consultation Paper on Framework of IT Resilience Index for Market Infrastructure Institutions (MIIs)" | www.sebi.gov.in
   Claims: Proposes creation of an 'IT Resilience Index' (ITRI) for market infrastructure institutions, computed periodically on a pre-decided set of parameters. / States the objective is to let MIIs compare the health/efficacy of their IT systems over time and to create a uniform set of metrics and weights to compare ITRI across MIIs. / Notes MIIs had already built a working model of the index, discussed in meetings of SEBI's Technical Advisory Committee (TAC).
   Excerpt: The objective of the consultation paper is to seek views on creation of IT Resilience Index (ITRI) for MIIs that would be computed periodically on a pre-decided set of parameters and which would provide insights to the MII on health of its IT systems across various dimensions. Based on the discussions with MIIs, an initial framework of ITRI for MIIs was formulated. The MIIs have implemented a working model of such index and the results were subsequently discussed in various meetings of SEBI's Technical Advisory Committee (TAC).
---
## SNAPSHOT Se9118ef529
CUTOFF DATE (today): 2026-03-16
Regulator: SEBI (IN)
Matter: SEBI consultation: permitting net settlement of funds for Foreign Portfolio Investor cash-market transactions
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S6d8a68496f
CUTOFF DATE (today): 2026-03-16
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing minimum investment in Social Impact Funds and NPO registration/minimum-subscription requirements on the Social Stock Exchange
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-02-09 | official-forward (B) | consultation_paper | "Review of minimum value of investment by individual investors in Social Impact Fund under SEBI AIF Regulations, 2012 and review of requirements related to registration period of NPOs and minimum subscription under SEBI I" | www.sebi.gov.in
   Claims: Proposes to reduce the minimum value of investment by individual investors in Social Impact Funds (AIF Regulations) from the existing rupees two lakh to rupees one thousand. / Notes the proposed rupees-one-thousand figure would align the Social Impact Fund minimum with the minimum application size already prescribed (from March 19, 2025) for Zero Coupon Zero Principal (ZCZP) instruments under ICDR Regulations. / Proposes related changes to NPO registration-period requirements and minimum-subscription requirements under ICDR Regulations, 2018 for the Social Stock Exchange. / States the objective is to facilitate wider retail participation on the Social Stock Exchange.
   Excerpt: The objective of this consultation paper is to solicit comments / views / suggestions from the public and other stakeholders on the proposals relating to review of minimum value of investment in Social Impact Funds and the requirement of minimum subscription and registration period for Not for Profit Organizations on Social Stock Exchange under the relevant SEBI Regulations... it is proposed that the minimum value of investment by individual investors in Social Impact Fund of AIF may be reduced from the existing rupees two lakh to rupees one thousand.
---
## SNAPSHOT S07150dde93
CUTOFF DATE (today): 2025-12-08
Regulator: FDA (US)
Matter: FDA draft guidance: Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S416cfef0e4
CUTOFF DATE (today): 2023-11-21
Regulator: FDA (US)
Matter: FDA draft guidance: Digital Health Technologies for Remote Data Acquisition in Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2021-12-23 | official-forward (B) | draft_guidance_availability_notice | "Digital Health Technologies for Remote Data Acquisition in Clinical Investigations; Draft Guidance for Industry, Investigators, and Other Stakeholders; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, investigators, and other stakeholders entitled "Digital Health Technologies for Remote Data Acquisition in Clinical Investigations." This guidance provides recommendations to sponsors, i
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, investigators, and other stakeholders entitled "Digital Health Technologies for Remote Data Acquisition in Clinical Investigations." This guidance provides recommendations to sponsors, investigators, and other stakeholders on the use of digital health technologies (DHTs) to acquire data remotely from participants in clinical investigations evaluating medical products. DHTs may take the form of hardware and/or software and may be used to gather health-related information from study participants and transmit that information to study investigators and/or other authorized parties to evaluate the safety and effectiveness of medical products.
---
## SNAPSHOT Sfa5b439710
CUTOFF DATE (today): 2023-06-22
Regulator: FDA (US)
Matter: FDA draft guidance: Chronic Rhinosinusitis With Nasal Polyps: Developing Drugs for Treatment
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Se4327836d5
CUTOFF DATE (today): 2025-12-17
Regulator: SEBI (IN)
Matter: SEBI consultation: simplifying documentation and raising the threshold for issuance of duplicate securities certificates
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2025-11-25 | official-forward (B) | consultation_paper | "Ease of doing investment - Review of simplification of procedure and standardization of formats of documents for issuance of duplicate securities certificates" | www.sebi.gov.in
   Claims: Proposes raising the value threshold for simplified duplicate-securities documentation from the existing Rs 5 lakh. / Proposes a standardised Affidavit-cum-Indemnity bond format for duplicate-certificate issuance. / Proposes removing notarisation of the Affidavit-cum-Indemnity bond for low-value cases and rationalising documentation for higher-value cases.
   Excerpt: SEBI, vide para 22 of Master Circular for Registrars to an Issue and Share Transfer Agents ('RTAs') dated June 23, 2025, has inter-alia prescribed the documentary and procedural requirements for issuance of duplicate share certificates... if the value of securities as on the date of submission of application, does not exceed Rs. 5 Lakhs, the conditions mentioned in (i) and (ii) above are not required to be complied with.
---
## SNAPSHOT S035aa630f9
CUTOFF DATE (today): 2024-09-04
Regulator: FDA (US)
Matter: FDA draft guidance: Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning-Enabled Device Software Functions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sc297df683d
CUTOFF DATE (today): 2023-02-13
Regulator: FDA (US)
Matter: FDA draft guidance: The Use of Published Literature in Support of New Animal Drug Applications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-04-20 | official-forward (B) | draft_guidance_availability_notice | "The Use of Published Literature in Support of New Animal Drug Applications; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry #106 entitled "The Use of Published Literature in Support of New Animal Drug Applications." This draft guidance, when finalized, will replace the existing final guidance #106, "The Use of
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry #106 entitled "The Use of Published Literature in Support of New Animal Drug Applications." This draft guidance, when finalized, will replace the existing final guidance #106, "The Use of Published Literature in Support of New Animal Drug Approval," which FDA published in August 2000 and which specifically addressed the use of a single article to support drug approval. This revision of the guidance document considers multiple uses of the scientific literature, including narrative reviews, systematic reviews, and meta-analyses to support approval of a new animal drug.
---
## SNAPSHOT S936eb64977
CUTOFF DATE (today): 2023-01-13
Regulator: FDA (US)
Matter: FDA draft guidance: Peripheral Percutaneous Transluminal Angioplasty and Specialty Catheters-Premarket Notification (510(k)) Submissions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S4dbc738e7b
CUTOFF DATE (today): 2022-09-07
Regulator: FDA (US)
Matter: FDA draft guidance: Drug Products Labeled as Homeopathic
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (2 item(s), chronological):
[E1] 2019-10-24 | official-forward (B) | draft_guidance_availability_notice | "Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for FDA staff and industry entitled "Drug Products Labeled as Homeopathic." The revised draft guidance, like the original version, describes how FDA intends to prioritize enforcement and regul
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for FDA staff and industry entitled "Drug Products Labeled as Homeopathic." The revised draft guidance, like the original version, describes how FDA intends to prioritize enforcement and regulatory action with regard to drug products, including biological products, labeled as homeopathic and marketed in the United States without the required FDA approval that potentially pose higher risk to public health. In response to comments received, we have revised the draft guidance and are reissuing it in draft form to enable the public to review and comment before it is finalized.
[E2] 2020-03-13 | official-forward (B) | comment_period_extension_notice | "Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry; Extension of Comment Period" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is extending the comment period for the notice entitled "Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry" that appeared in the Federal Register of October 25, 2019. The Agency is taking this act
   Excerpt: The Food and Drug Administration (FDA or Agency) is extending the comment period for the notice entitled "Drug Products Labeled as Homeopathic; Draft Guidance for Food and Drug Administration Staff and Industry" that appeared in the Federal Register of October 25, 2019. The Agency is taking this action to allow interested persons additional time to submit comments.
---
## SNAPSHOT Se0efc50fd6
CUTOFF DATE (today): 2023-11-06
Regulator: FDA (US)
Matter: FDA draft guidance: Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-03-10 | official-forward (B) | draft_guidance_availability_notice | "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance entitled "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs." This revised draft guidance addresses the verification systems that manufacturers, repa
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance entitled "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs." This revised draft guidance addresses the verification systems that manufacturers, repackagers, wholesale distributors, and dispensers must have in place to comply with the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Supply Chain Security Act (DSCSA). Specifically, this revised draft guidance covers the statutory verification system requirements that include the quarantine and investigation of a product determined to be suspect and the quarantine and disposition of a product determined to be illegitimate. The revised draft guidance also addresses the statutory requirement for notification to the Agency of a product that has been cleared by a manufacturer, repackager, wholesale distributor, or dispenser (also referred to as "trading partners") after a suspect product investigation because it is determined that the product is not an illegitimate product. Finally, the revised draft guidance addresses the statutory requirement for responding to requ
---
## SNAPSHOT S283e3f047b
CUTOFF DATE (today): 2022-04-23
Regulator: FDA (US)
Matter: FDA draft guidance: Select Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.